Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Terminated 3Recruiting 3Completed 3Active not recruiting 2Not yet recruiting 1Available 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 111Gastrointestinal 32Thoracic 25Genitourinary 24Breast 23Head & Neck 20Dermatologic 10Sarcoma 7Lymphoid 5Other solid neoplasm 3Plasma cell 2Other hematologic neoplasm 2CNS 2Other neoplasm 1NET 1Endocrine 1Classical hematology 1

Conditions

Multiple Myeloma 292Lymphoma 45Recurrence 31Neoplasms, Plasma Cell 28Hematologic Neoplasms 25Smoldering Multiple Myeloma 20Lymphoma, Non-Hodgkin 20Neoplasms 13Leukemia, Lymphocytic, Chronic, B-Cell 11Myelodysplastic Syndromes 10Leukemia 10Immunoglobulin Light-chain Amyloidosis 10Leukemia, Myeloid, Acute 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Myeloproliferative Disorders 8Hodgkin Disease 8Waldenstrom Macroglobulinemia 7Lymphoma, Mantle-Cell 6Prostatic Neoplasms 5Paraproteinemias 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Breast Neoplasms 5Lymphoproliferative Disorders 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Hematologic Diseases 4Colorectal Neoplasms 4Anemia, Refractory, with Excess of Blasts 4Anemia, Aplastic 4

Interventions

ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Trastuzumab 1Sunitinib 1Specimen Handling 1PF-05280014 1Ontruzant 1Ogivri 1Nuclear Medicine Department, Hospital 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1HhAntag691 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Endometrial Neoplasms × Plasma cell × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04000880 2025-06-12

AMPLIFY

University of Alabama at Birmingham

Phase NA Active not recruiting
603 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidPlasma cell

Breast Neoplasms, Kidney Neoplasms, Lymphoma, Non-Hodgkin, Motor Activity, Multiple Myeloma, Ovarian Neoplasms, Prostatic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡